Troy O. Harasym

3.0k total citations
45 papers, 2.2k citations indexed

About

Troy O. Harasym is a scholar working on Biomaterials, Molecular Biology and Epidemiology. According to data from OpenAlex, Troy O. Harasym has authored 45 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Biomaterials, 21 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in Troy O. Harasym's work include Nanoparticle-Based Drug Delivery (23 papers), Hepatitis B Virus Studies (10 papers) and RNA Interference and Gene Delivery (9 papers). Troy O. Harasym is often cited by papers focused on Nanoparticle-Based Drug Delivery (23 papers), Hepatitis B Virus Studies (10 papers) and RNA Interference and Gene Delivery (9 papers). Troy O. Harasym collaborates with scholars based in Canada, United States and Australia. Troy O. Harasym's co-authors include Lawrence D. Mayer, Paul Tardi, Marcel B. Bally, Sharon A. Johnstone, Steven M. Ansell, Natashia Harasym, Sean C. Semple, Michael J. Hope, Sandra K. Klimuk and David Bermudes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Troy O. Harasym

44 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Troy O. Harasym Canada	21	1.3k	915	483	339	306	45	2.2k
Paul Tardi Canada	25	1.4k 1.0×	1.2k 1.4×	603 1.2×	359 1.1×	474 1.5×	52	2.5k
Sharon A. Johnstone Canada	15	993 0.7×	850 0.9×	450 0.9×	196 0.6×	251 0.8×	20	1.7k
Serena Mazzucchelli Italy	30	1.1k 0.8×	785 0.9×	637 1.3×	228 0.7×	413 1.3×	91	2.4k
Daniel Rosenblum United States	18	1.8k 1.3×	1.1k 1.2×	1.1k 2.4×	100 0.3×	345 1.1×	39	3.3k
Joseph A. Reddy United States	30	1.5k 1.1×	764 0.8×	472 1.0×	93 0.3×	763 2.5×	49	2.9k
Tracy R. Daniels‐Wells United States	26	1.5k 1.1×	644 0.7×	454 0.9×	400 1.2×	553 1.8×	51	3.0k
Dana Masin Canada	25	1.3k 0.9×	1.1k 1.3×	464 1.0×	65 0.2×	532 1.7×	37	2.2k
Wenxue Ma United States	26	1.1k 0.8×	453 0.5×	352 0.7×	192 0.6×	624 2.0×	84	2.5k
Jonathan D. Ashley United States	13	721 0.5×	551 0.6×	273 0.6×	190 0.6×	157 0.5×	16	1.3k
Arcadio Chonn Canada	19	2.2k 1.7×	1.4k 1.6×	490 1.0×	114 0.3×	257 0.8×	23	3.5k

Countries citing papers authored by Troy O. Harasym

Since Specialization

Citations

This map shows the geographic impact of Troy O. Harasym's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Troy O. Harasym with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Troy O. Harasym more than expected).

Fields of papers citing papers by Troy O. Harasym

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Troy O. Harasym. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Troy O. Harasym. The network helps show where Troy O. Harasym may publish in the future.

Co-authorship network of co-authors of Troy O. Harasym

This figure shows the co-authorship network connecting the top 25 collaborators of Troy O. Harasym. A scholar is included among the top collaborators of Troy O. Harasym based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Troy O. Harasym. Troy O. Harasym is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lam, Angela M., Muhammad Sheraz, Fei Liu, et al.. (2024). Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161. Viruses. 16(3). 323–323. 5 indexed citations

Mesaros, Eugen F., Andrew G. Cole, Steven G. Kultgen, et al.. (2024). Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators. ACS Medicinal Chemistry Letters. 15(9). 1627–1634. 2 indexed citations

Cole, Andrew G., Steven G. Kultgen, Nagraj Mani, et al.. (2024). Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. Journal of Medicinal Chemistry. 67(18). 16773–16795. 4 indexed citations

Dorsey, Bruce D., Min Gao, Fei Liu, et al.. (2024). Structure–Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer. Journal of Medicinal Chemistry. 67(2). 1421–1446. 4 indexed citations

Thi, Emily P., Xin Ye, Nicholas M. Snead, et al.. (2024). Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic. ACS Infectious Diseases. 10(10). 3640–3649. 6 indexed citations

Thi, Emily P., Andrew G. Cole, Seyma Ozturk, et al.. (2022). Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients. Journal of Hepatology. 77. S848–S848. 1 indexed citations

Stern, Stęphan T., Peng Zou, Sherwin Xie, et al.. (2013). Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. Journal of Controlled Release. 172(2). 558–567. 8 indexed citations

Kim, Hyun Pyo, Brigitte Gerhard, Troy O. Harasym, Lawrence D. Mayer, & Donna E. Hogge. (2011). Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Experimental Hematology. 39(7). 741–750. 64 indexed citations

Lim, Wah-Seng, Paul Tardi, Nancy Dos Santos, et al.. (2010). Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leukemia Research. 34(9). 1214–1223. 118 indexed citations

10.

Lim, Wah-Seng, Paul Tardi, Xiaowei Xie, et al.. (2010). Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leukemia & lymphoma. 51(8). 1536–1542. 26 indexed citations

11.

Tardi, Paul, Nancy Dos Santos, Troy O. Harasym, et al.. (2009). Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Molecular Cancer Therapeutics. 8(8). 2266–2275. 98 indexed citations

12.

Ansell, Steven M., Sharon A. Johnstone, Paul Tardi, et al.. (2008). Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications. Cancer Research. 68. 5734–5734. 3 indexed citations

13.

Tardi, Paul, Sharon A. Johnstone, Natashia Harasym, et al.. (2008). In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leukemia Research. 33(1). 129–139. 288 indexed citations

14.

Webb, Murray S., Sharon A. Johnstone, Ryan Gallagher, et al.. (2006). In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. European Journal of Pharmaceutics and Biopharmaceutics. 65(3). 289–299. 29 indexed citations

15.

Chiu, Gigi N.C., Troy O. Harasym, Paul Tardi, Marcel B. Bally, & Dawn Waterhouse. (2006). Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations. Letters in Drug Design & Discovery. 3(10). 704–713. 1 indexed citations

16.

Johnstone, Sharon A., Pierrot Harvie, Salam Kadhim, et al.. (2005). Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models. Cancer Research. 65. 329–329. 3 indexed citations

17.

Semple, Sean C., Troy O. Harasym, Kathy A. Clow, et al.. (2005). Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid. Journal of Pharmacology and Experimental Therapeutics. 312(3). 1020–1026. 167 indexed citations

18.

Mayer, Lawrence D., Troy O. Harasym, Natashia Harasym, et al.. (2004). A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer. Cancer Research. 64. 126–127. 2 indexed citations

19.

Semple, Sean C., Sandra K. Klimuk, Troy O. Harasym, et al.. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1510(1-2). 152–166. 379 indexed citations

20.

Semple, Sean C., Sandra K. Klimuk, Troy O. Harasym, & Michael J. Hope. (2000). Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods in enzymology on CD-ROM/Methods in enzymology. 313. 322–341. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact